Piper Jaffray analyst David Amsellem upgraded Bausch Health Companies Inc (NYSE: BHC) to Hold today and set a price target of $19. The company’s shares closed yesterday at $23.54.
According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -1.8% and a 44.1% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Eagle Pharmaceuticals Inc, Amphastar Pharmaceuticals, and Supernus Pharmaceuticals.
Currently, the analyst consensus on Bausch Health Companies Inc is a Hold with an average price target of $26.56, representing a 12.8% upside. In a report issued on August 31, H.C. Wainwright also reiterated a Hold rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $27.79 and a one-year low of $10.94. Currently, Bausch Health Companies Inc has an average volume of 6.62M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
